FibroBiologics announced the issuance of a patent from the European Patent Office covering methods and compositions for the treatment of cancer utilizing fibroblasts that have been modified to enhance their ability to deliver one or more anti-cancer agents to an individual. This method uses modified fibroblasts to deliver tumor-inhibiting agents directly to cancer cells. The fibroblasts would be engineered to enhance their natural ability to target cancerous tissues, and then loaded with therapeutic agents to fight primary, metastatic, or treatment-resistant tumors. Modifying the fibroblasts in this manner may make them more effective in targeting cancer cells and delivering treatment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBLG:
- Maxim starts FibroBiologics at Buy, sees fibroblast therapy as ‘more potent’
- FibroBiologics initiated with a Buy at Maxim
- FibroBiologics engages Southern Star Research as CRO in Australia
- FibroBiologics files patent application for fibroblast cell-based technology
- FibroBiologics initiated with a Buy at EF Hutton